Design Therapeutics, Inc.

Contributing Author

Recent Articles by Design Therapeutics, Inc.

Nov-05	Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results DSGN GlobeNewswire
Sep-10	Design Therapeutics Appoints Justin Gover to Board of Directors DSGN GlobeNewswire
Aug-27	Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference DSGN GlobeNewswire
Aug-07	Design Therapeutics Highlights Progress Across Lead GeneTAC Programs and Reports Second Quarter 2025 Financial Results DSGN GlobeNewswire
Jun-04	Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2 DSGN GlobeNewswire
May-28	Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference DSGN GlobeNewswire
May-13	Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference DSGN GlobeNewswire
May-07	Design Therapeutics Highlights Momentum Across Lead GeneTAC Programs and Reports First Quarter 2025 Financial Results DSGN GlobeNewswire
May-01	Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy DSGN GlobeNewswire